Trials / Completed
CompletedNCT03516071
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
A Multicenter, Randomized, Open-label, Phase II Clinical Study to Evaluate the Efficacy and Safety of Brivanib Alaninate (ZL-2301) Combined With Best Supportive Care (BSC) and Pharmacokinetic Profiles of Brivanib Alaninate in Patients With Advanced Hepatocellular Carcinoma (HCC) Failed or Intolerant of Standard Systemic Chemotherapy and/or Sorafenib
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Zai Lab (Shanghai) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, Open-label, Randomized, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Brivanib in Patients with Previously Treated Advanced Hepatocellular Carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brivanib 800 mg, QD | Brivanib Alaninate 800 mg QD, PO |
| DRUG | Brivanib 400 mg, BID | Brivanib Alaninate 400 mg BID, PO |
Timeline
- Start date
- 2017-05-17
- Primary completion
- 2018-11-09
- Completion
- 2019-07-19
- First posted
- 2018-05-04
- Last updated
- 2019-09-04
Locations
15 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03516071. Inclusion in this directory is not an endorsement.